×

RNS Number : 2915I

Deepverge PLC

11 December 2020

 

11 December 2020

 

DeepVerge PLC

 

("DeepVerge" or "the Company")

 

 

New Labskin service 'soft  launched' in August already nets £400,000 in completed orders in Q4

 

Service has attracted new household name clients

 

 

DeepVerge (LSE:DVRG.L), the environmental and life science AI company, is pleased to announce a new R&D service, launched in August 2020, has already generated £400,000 in completed sales in Q4 with agreements with 10 new clients that had previously not used Labskin services. These agreements include framework Master Services Agreements with 2 of the world's largest suppliers of consumer products related to skincare.

 

The new service, designed to quickly validate the impact of ingredients such as probiotics and prebiotics on the skin microbiome, clones the human skin microbiome using six microbial strains and delivers real world environment results that mirror the impact of treatments and therapeutics on real human skin.

 

The new R&D service adds to the existing client offering. It increases revenue per client and delivers higher value test services on ingredients used in an expansive range of products – from anti-viral, to shampoos to babies' nappies.  The new service replicates skin conditions of the scalp, face, mouth and abdomen. It also utilises AI which has significantly improved the speed and accuracy of testing ingredients on virtual skin models.

 

 

Gerard Brandon, CEO of DeepVerge, Commented:

 

"When we designed this new service we built on three key platforms : Labskin's ability to grow human skin, its expertise in replicating the skin's microbial environment from different parts of the body and its increasing use of AI and data which helps with speed, accuracy and insights. While we will fully launch the product at conferences across all regions in 2021, it has already resulted in significant interest and orders from existing and new clients as well as from new clients in new sectors/markets.

 

The Labskin division has become a recognised global leader in cloning and testing real-world human skin microbiome in a laboratory with a rapidly expanding order book from a growing blue chip client base. Since September 2019, the team has increased revenue per client exponentially by offering multiple value-added solutions beyond its core laboratory testing services which lower client development costs of product information validation enabling new products get to market faster."

 

For further information please contact:

DeepVerge plc	Gerard Brandon, CEO	+44 (0) 7340 055 648
SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	+44 (0) 113 370 8974
Turner Pope Investments (TPI) Limited (Broker)	Andy Thacker/Zoe Alexander	+44 (0) 20 3657 0050

 

About DeepVerge plc (www.deepverge.com)

DeepVerge is a scientific research and AI-as-a-Service company focused on production and analysis of bacteria, virus and toxins utilising artificial intelligent data analytics in regulatory technology, from scientifically proving the impact of skincare product claims on skin microbiome for top 20 global cosmetic company clients to remotely detecting water contamination in real-time.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCURVNRRRUUAAA

Close

×

Volvere is an industrial holding company that invests in or acquires companies which require growth capital. 

Further information can be found on the Company’s website: https://www.volvere.co.uk/

Close

×

RNS Number : 9798H

Osirium Technologies PLC

09 December 2020

 

9 December 2020

REACH

 

 

Osirium Technologies plc

("Osirium" or "Group")

 

Contract win with additional major UK Ambulance Service

 

Osirium Technologies plc (AIM: OSI.L), a leading vendor of cloud-based cybersecurity software, is pleased to announce a contract win with an additional major regional UK Ambulance Service.

 

The new contract represents a further instance of Osirium displacing an incumbent PAM provider and being selected in preference to other PAM vendors. The initial order is for the Osirium PAM platform including the Privileged Access Management, Privileged Task Management and Privileged Session Management modules for 375 devices over a 36-month term. 24/7 support, professional services and training are included in the contract.

The order continues Osirium's success in 2020 in securing business from the UK Ambulance Service sector in conjunction with ITHealth, an approved reseller partner specialising in cybersecurity for healthcare service providers. Key factors in the selection are Osirium's local presence and 24/7 support capabilities, flexibility of licensing, breadth of PAM functionality, and ease of deployment and use.

The principal initial d river for the client in this contract is demonstrating compliance with the NHS Data Protection Security Toolkit directive, to provide assurance of good data security practices and correct handling of personal information. The Osirium PAM platform will be used to carry out a number of functions across a mixed Windows and networking environment, including backups, controlling access, managing credentials, and providing a comprehensive, end to end audit trail. The client also sees real value in applying Osirium's task and process automation capabilities. This allows them to securely delegate activities requiring privileges to staff outside the immediate project team, and, thus, reduce workload strain on specialist IT resources.

Subsequent phases will also include secure management of 3rd party access to the infrastructure, as well as additional controls for internal access.

Following the announcement of a contract win with a major UK communications and mobile services provider on 2 December 2020, this new contract is a further endorsement of Osirium's strategy and strong commercial momentum.

 

David Guyatt, Chief Executive Officer, commented : "I am delighted that Osirium has been able to secure another win in the NHS and Emergency Services sector and, yet again, displace an incumbent PAM supplier. This contract endorses multiple aspects of our strategy: our focus on simplicity and ease of deployment that other vendors fail to match; our partnership with quality specialist integrators; our commercial flexibiltity and agility in securing this order within a three month sales cycle; and our commitment to providing ourstanding support to our customers." 

 

 

–  Ends –

For further information:

Osirium Technologies plc	Tel: +44 (0) 118 324 2444
David Guyatt, Chief Executive Officer Rupert Hutton, Chief Financial Officer www.osirium.com
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)	Tel: +44 (0) 20 7710 7600
Fred Walsh / Richard Short
Alma (Financial PR) David Ison / Josh Royston / Kieran Breheny	Tel: +44 (0) 203 405 0205

 

Notes to Editors:

Osirium Technologies plc (AIM: OSI) operates in one of the fastest growing parts of the cybersecurity market and is a leading vendor of Privileged Access Security solutions. Osirium's cloud-based products protect critical IT assets, infrastructure and devices by preventing targeted cyber-attacks from directly accessing Privileged Accounts, removing unnecessary access and powers of Privileged Account users, deterring legitimate Privileged Account users from abusing their roles and containing the effects of a breach if one does happen.

Osirium has defined and delivered what the Directors view as the next generation Privileged Access Management solution. Osirium's award-winning Privileged Task Management module further strengthens Privileged Account Security by minimising the cyber-attack surface and delivering an impressive return on investment benefits for customers. Building on Osirium's Privileged Task Management module, in May 2019 Osirium launched Privileged Process Automation, providing a highly-flexible platform for automating essential IT processes to set a new benchmark in IT Process Automation. This was followed by the launch of Privileged Endpoint Manager in December 2019, bringing the total portfolio to three complementary solutions.

Founded in 2008 and with its headquarters in Reading, UK, the Group was admitted to AIM in April 2016. For further information please visit www.osirium.com.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAEAKAPESDEFFA

Close

×

RNS Number : 9286H

e-Therapeutics plc

08 December 2020

 

e-therapeutics plc

("e-therapeutics" or the "Company")

 

COVID-19 Project Update

 

 

 

Oxford, UK, 8 December 2020 – e-therapeutics plc (AIM: ETX) announces the results of experimental testing on the compounds for the treatment of COVID-19 identified using its proprietary Network-driven Drug Discovery (NDD) platform.

In March 2020, the Company announced its intention to deploy its network biology platform to identify clinical stage compounds that either singly or in combination could be repurposed rapidly to treat COVID-19. We chose to approach this by focussing on therapeutic strategies that target host systems, thereby minimising the risk of resistance and potentially being effective for the treatment of other viral infections.

From our previous work using network models of SIRS (Systemic inflammatory response syndrome) seen in indications such as sepsis, we had identified a class of small molecule compounds, a mechanism and target that was able to silence the 'cytokine storm' generated in human blood cells by a range of inflammatory triggers. In March 2020, we undertook an in silico analysis of data sets from human cells infected with SARS-CoV-2 and generated network models of the cellular machinery that the virus had 'hijacked'. Analysis of both our SIRS work and the SARS-CoV-2 networks revealed a key common process which was simultaneously important to the virus and the hyperinflammatory response. Our platform predicted that inhibition of the same target, GRP94, that was effective in suppressing hyperinflammation would also be effective in disrupting the virus's ability to replicate.

In May 2020, small molecule compounds predicted by our platform were tested in validated SARS-CoV-2 in vitro assays at WuXi AppTech. These compounds showed potent anti-inflammatory and anti-viral activity. We report here that in vitro assays have confirmed our in silico predictions and we have identified a clear mechanism, target and clinical stage compounds. These compounds are active against GRP94 and have anti-inflammatory and anti-viral activity against Sars-CoV-2. This activity generalises to other alpha and beta coronaviruses and is expected to be generically applicable, raising the prospect of utility against both existing coronaviruses that cause serious disease such as SARS and MERS and against new emergent strains of coronavirus.

The clinical stage compounds identified have been developed in humans for alternative indications and have an established safety profile in man. These, and other selective compounds sharing this target, could be rapidly deployed into clinical trials to treat patients with serious Covid-19 disease. Given our mechanistic insights, it would also be feasible to develop novel, highly selective drugs against GRP94. We continue to work on repurposable combinations using our platform and have compound combinations currently in testing. We anticipate data that will enhance our understanding further in Q1 2021.

Chairman & CEO Ali Mortazavi said:

" e-therapeutics' platform has the ability to start with any biological process of relevance to disease and to identify compounds and targets that can modulate that process in a therapeutic setting. This data set is a strong validation of our platform and the network biology approach to drug discovery. e-therapeutics' computational biology platform is capable of discovering new chemical matter, novel drug targets and uncovering new mechanisms. Here, we have deployed that capability to investigate known compounds in a novel context. We have uncovered new mechanisms that mitigate infection-induced hyperinflammation as well discovering a potent anti-viral strategy. Our findings have highlighted Bardoxolone Methyl which is already the subject of an investigator led COVID-19 trial (NCT04494646).

The surprise finding of this compound's anti-viral activity alongside its well observed anti-inflammatory properties has led us to file a patent (GB2017631.9) which describes the use of Bardoxolone and related compounds to treat Covid-19 and other viral diseases. Previous knowledge of similar compounds has focused on the activation of the NRF2 pathway. Here, we show that both the anti-viral and anti-inflammatory properties we have observed depend on GRP94. We demonstrate that other selective GRP94 inhibitors may also be active anti-virals against a range of coronaviruses. Should Bardoxolone Methyl be progressed from its Phase 2 safety evaluation in NCT04494646 into Phase 3, we would be happy to share our anti-viral analysis with the sponsor.

To date, no compounds with this type of potent dual activity have been reported and clinical approaches have focused on combination drug therapies using anti-inflammatory compounds such as dexamethasone combined with anti-virals such as Remdesivir. Irrespective of our findings for Bardoxolone, we believe that our project will open deeper interest in selective GRP94 inhibitors and GRP94 as a possible target for future development of therapeutics not only for COVID induced hyper-inflammation/infection but potentially other viral infections. A presentation can be found on our website at : https://www.etherapeutics.co.uk/wp-content/uploads/2020/12/COVID-Project-Update-05122020.pdf The company intends to publish this work in a highly regarded scientific journal in the coming months."

-Ends-

 

 

For further information, please contact:

 

e-therapeutics plc Ali Mortazavi, CEO	Tel: +44 (0)1993 883 125 www.etherapeutics.co.uk
Numis Securities Limited Freddie Barnfield/Duncan Monteith (Nominated Adviser)  James Black (Corporate Broking)	Tel: +44 (0) 207 260 1000  www.numis.com

 

About e-therapeutics plc

 

e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and access to big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.

 

e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.

 

e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

UPDUWRARRNUURAA

Close

×

RNS Number : 3517H

N4 Pharma PLC

03 December 2020

 

3 December 2020

N4 Pharma plc

("N4 Pharma" or the "Company")

 

Formulation Work Update

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide the following update on its ongoing research collaboration agreement with Nanomerics Limited ("Nanomerics").

 

As announced on 11 February 2020, the Company initiated the first phase of research to test the stability of different formulations of Nuvec® loaded with a well characterised plasmid DNA. The Company is pleased to report that, in addition to not degrading the plasmid DNA, which it announced on 5 November 2020, Nuvec® formulations that had been freeze dried and then stored for 14 days either at room temperature or at four degrees Celsius, showed no significant drop in in vitro transfection capability following reconstitution compared to fresh formulations.

 

In parallel to continued work on analysing stability duration, different formulations will now be chosen to move forward into phase two of the work programme testing the efficacy of the dried and reconstituted plasmid DNA in an in vivo antibody generation model .

 

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"Demonstrating that Nuvec® loaded with a plasmid DNA can be dried, stored at convenient temperatures and reconstituted without any drop in transfection is a significant step forward in our formulation development work.

 

"The recent success of Pfizer and Moderna with an mRNA Covid-19 vaccine shows the potential for nucleic acid vaccines. However, it also highlights that these vaccines have certain limitations, in that they often require extreme storage conditions.

 

"Although vaccine efficacy is predominantly determined by the selected nucleic acid antigen, having a stable, easy to store and easy to use vaccine is crucial in helping vaccine acceptance and uptake. A formulation stable at room temperature or even refrigerated can represent significant cost savings in vaccine transportation, storage and administration. We believe, to the extent that Nuvec® as a delivery platform can provide a solution in this area, it could be of significant interest to multiple vaccine developers.

 

"Work will continue in this area and will add to the breadth of proof of concept data we are building for the use of Nuvec® as a delivery system for vaccines and cancer treatments."

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

 

Enquiries:

 

N4 Pharma plc
Nigel Theobald, CEO	Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP	Tel: +44(0)20 3470 0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Turner Pope Investments (TPI) Limited	Tel: +44(0)20 3657 0050
Joint Broker
Andy Thacker
IFC Advisory Ltd Financial PR Graham Herring Zach Cohen	Tel: +44(0)20 3934 6630

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre-clinical and clinical programs, N4 Pharma will seek to receive up-front payments, milestone payments and ultimately royalty payments once products reach the market.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCBCBDDUBGDGGD

Close

×

RNS Number : 1788H

IDOX PLC

02 December 2020

 

2 December 2020

RNS Reach

 

Idox plc

('Idox' or the 'Group' or the 'Company')

 

Contract Win

Idox partnership to deliver election e-Counting solution to Scottish Government

ldox (AIM: IDOX), a leading supplier of specialist information management software and solutions,  today announces a contract with the Scottish Government and Scottish Local Authorities, to deliver the electronic counting of ballot papers for the scheduled Local Authority elections in 2022 and future Scottish elections.

Working in partnership with Fujitsu and Elite Training, the five-year contract, won under open tender, will see Idox provide e-Counting election support for the Scottish Government and Scottish Local Authorities for the third consecutive time, having been selected to provide software and print management services in the 2016 and 2017 Scottish Local Government elections.

David Meaden, Chief Executive Officer of Idox said:

"Our strategic partnership with Fujitsu and Elite Training provides a market-leading e-Counting solution that will help drive efficiency and improve the Scottish elections' process. The contract marks an important win for Idox, showcasing our full capabilities in electoral services whilst improving our revenue visibility for FY21 and beyond."

-Ends-

Enquiries :

Idox plc          +44 (0) 870 333 7101

Chris Stone, Non-Executive Chairman
David Meaden, Chief Executive
Rob Grubb, Chief Financial Officer


MHP Communications                             +44 (0) 203 128 8170
Reg Hoare / James Bavister / Amy O'Sullivan                                                                           [email protected]

About Idox plc

For more information see  www.idoxplc.com   @Idoxgroup

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRATBBFTMTTMBRM

Close

×

RNS Number : 8402G

ValiRx PLC

30 November 2020

 

30 November 2020

("ValiRx", the "Company" or the "Group")

 

VAL201 Clinical Trial Full Data Results

 

Full dataset confirms VAL201 is a safe and well-tolerated drug candidate

 

Company to host webcast for investors on 8 December 2020 at 2 pm GMT

 

London, UK – ValiRx plc ("ValiRx", AIM:VAL), a clinical stage drug development company, is pleased to report that it has received the full dataset to be used for the Clinical Study Report from the Phase 1/2 clinical trial of its lead asset, VAL201, for the treatment of locally advanced or metastatic prostate cancer and performed at University College Hospital (UCLH), London. This expands the positive headline results announced on 28 September 2020.

 

The dataset provides a complete breakdown of the full data of safety and tolerability as well as evidence for encouraging disease impact as observed during the clinical trial.  This data will be used to formulate the Clinical Study Report and to report the results on the www.clinicaltrials.gov database.  Additional detailed analysis of the results will form the basis of peer-reviewed journal publications.

 

The full dataset is available to download on the Company website, https://www.valirx.com/our-pipeline/val201 .

 

Key details of the findings:

 

Recruitment Criteria

· Twelve patients were recruited according to the criteria of having incurable, locally advanced or metastatic prostate cancer with rising PSA[1] (Prostate-Specific Antigen) on three consecutive samples and absent or very mild prostate cancer-related symptoms.

· The demographics and a detailed breakdown of the patients recruited is provided in the download.

 

Disease Impact

· The headline results released in the Company announcement on 28 September 2020 highlighted the response rate of 54.5%, where response was confirmed by a lack of disease progression by PCWG2 (Prostate Cancer Working Group 2) criteria.  The dataset now received provides the detailed breakdown of this by providing both the PSA modulation afforded by the treatment, and the tumour response.

· The PSA data, a recognised surrogate of disease progression, shows two patients seeing a decrease in PSA during their treatment period, one of which maintained the decrease throughout the trial. An analysis of the doubling time of patients shows a statistically significant (p<0.05, two-tailed Wilcoxon Signed-Rank test for paired samples) increase in PSA doubling time comparing pre-treatment doubling time to post-treatment doubling time.  The PSA doubling time would be expected to be unchanged if the treatment was having no impact, so an increase in doubling time demonstrates a slowing rate of growth of PSA levels.

· The tumour response data demonstrates that patients did not have an increase in metastatic lesions during the treatment period, and that metastatic lesions already present did not grow at all in two out of three patients, suggesting a positive influence of VAL201 on the disease.

 

Safety and Tolerability

The further breakdown of the safety data confirms the well tolerated nature of the drug.

 

Additionally, the initial pharmacokinetic analysis supports the safety profile in confirming the drug is processed and cleared from the body in the manner expected.

 

The Company expects to publish the data on the National Institute of Health's (NIH) public database ClinicalTrials.gov, as well as produce research papers for peer-reviewed publications.

 

Investor Webcast

ValiRx will host a webcast for investors on Tuesday, 8 December 2020 at 2pm GMT to discuss the findings of the study.

 

· Prior to the webcast, questions can be submitted online to [email protected]

· During the webcast, questions can be submitted through the webcast link below.

 

To participate, please click on the link below at the designated time:

 

https://webcasting.brrmedia.co.uk/broadcast/5fc12476b19325729a9d841f

The webcast will be available on demand following a link on the Company's website after the broadcast.  This webcast replaces the usual monthly Q&A publication, and a written summary of questions with answers will be provided after the event.

 

Dr Suzy Dilly, Chief Executive Officer commented: "This data demonstrates the potential of VAL201 for further development towards a treatment for patients with prostate cancer.  Providing the data breakdown to support and explain the headline numbers is a crucial step and allows us to delve further into analysis of the results. The highly encouraging 54.5% response rate remains unchanged and being able to interrogate the data in more detail allows us to explore the possibilities for optimising the treatment through future trial with partners.

 

"We continue to share the dataset with potential industry partners who expressed an interest after the headline results were released in September 2020, and I look forward to the discussions that I am confident will arise as we evaluate all options for further clinical development.  We would like to thank the team for their hard work and our shareholders for their support."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The Directors of the Company take responsibility for this announcement.

 

Ends

 

For further information please contact:

 

ValiRx plc	Tel: +44 (0) 2476 796496 www.valirx.com
Suzanne Dilly, CEO	[email protected]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti	Tel: +44 (0) 20 7213 0880
Peterhouse Capital Limited (Sole Broker) Duncan Vasey / Lucy Williams / Eran Zucker	Tel: +44 (0) 20 7469 0930
Optimum Strategic Communications Supriya Mathur/ Shabnam Bashir	Tel: +44 (0) 20 8148 3040 [email protected]

 

 

About ValiRx plc

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

 

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

 

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process.  We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

 

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/

 

About VAL201

VAL201 is a short peptide being studied as a potential treatment for prostate cancer. The peptide structure is inspired by the naturally occurring androgen receptor and is designed to intercept and prevent the binding of the androgen receptor to SRC kinase – an enzyme implicated in cancerous cell growth pathways. By preventing the androgen-mediated activation of SRC kinase, VAL201 can potentially prevent cancerous cell proliferation (or growth) without interfering with other functions of either the androgen receptor or SRC kinase. This precision method, mimicking a natural process, proposes a high specificity of cancer treatment with a lower side effect profile. VAL201 was licensed from CRT (part of CRUK) in 2010 and developed through preclinical development into this clinical trial in patients with advanced prostate cancer. The study was held at University College Hospital (UCLH), London.

 

About the VAL201-001 clinical trial

The clinical trial: "A Phase I/II, Dose Escalation Study to Assess the Safety and Tolerability of VAL201 in Patients with locally Advanced or Metastatic Prostate Cancer and Other Advanced Solid Tumours" opened to recruitment in December 2014 and closed in January 2020.

 

Patients were scheduled for treatment of a once weekly injection of VAL201 in 3 week cycles for a maximum of 6 cycles.  A total of 12 patients received at least 1 dose of VAL201.

 

Patients were eligible if they were: Adult men (over the age of 18) with incurable locally advanced or metastatic prostate cancer who had relapsed following radiotherapy treatment, are in 'watchful waiting' or where a policy of intermittent hormone therapy had been decided.  Patients were expected to have no or only mild symptoms relating to their prostate cancer. (ClinicalTrials.gov identifier: NCT02280317)

 

About Prostate Cancer

Around 48,500 men are diagnosed with prostate cancer in the UK each year[2]. In men, it is the most common cancer in the UK.  Prostate cancer is most common in older men. On average each year 35 out of 100 (35%) of new cases are in men aged 75 and over.

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates.

 

Factors that could cause actual results to differ materially from those in the forward-looking statements include risks relating to unanticipated costs, liabilities or delays; failure or delays in research and development programs; the safety and efficacy of the Company's product candidates and the likelihood of clinical data to be positive and of such product candidates to be approved by the applicable regulatory authorities; unanticipated changes relating to competitive factors in the Company's industry; risks relating to the Company's capitalisation, resources and ownership structure, the availability of sufficient resources for company operations and to conduct or continue planned clinical development programs; the outcome of any legal proceedings; risks related to the ability to correctly estimate operating expenses; risks related to the ability to project future cash utilisation and reserves needed for contingent future liabilities and business operations; risks related to the changes in market prices of the Company's ordinary shares; the Company's ability to hire and retain key personnel; changes in law or regulations affecting the Company; international, national or local economic, social or political conditions that could adversely affect the Company and its business; conditions in the credit markets; risks associated with assumptions the Company makes in connection with its critical accounting estimates and other judgments.

 

 

 

---

[1]The PSA test is a blood test used primarily to screen for prostate cancer. The test measures the amount of prostate-specific antigen (PSA) in the blood. PSA is a protein produced by both cancerous and noncancerous tissue in the prostate gland.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCEANFNASEEFFA

Close

×

RNS Number : 4927F

Crimson Tide PLC

17 November 2020

 

Crimson Tide Plc

Contract Wins

 

Crimson Tide Plc (TIDE) is pleased to announce contract wins approaching £0.5m which demonstrate the appeal of mpro5 across sectors and the growing traction of its Internet of Things (IoT) capabilities.

Cadent, providers of the UK gas network and employing over 4000 staff, have invested in mpro5 within two of their four UK regions for the purpose of re-instatement works across the 82,000 miles of gas pipeline they manage.

The mpro5 platform has been deeply integrated with Cadent's SAP installation, allowing for real-time scheduling of remedial works to its multi-disciplinary re-instatement teams. The real-time data provided by mpro5 is already being used to ensure compliance with Local Authority guidelines and the Company is hopeful of a wider roll-out across all regions, and additional departments in due course.

Incentive QAS, the contract cleaning arm of Incentive FM – employing some 800 staff across the UK, have invested in mpro5 for the purposes of IoT-driven cleaning compliance at London's Citypoint skyscraper.

Using mpro5's proprietary IoT platform, areas throughout Citypoint are reporting real-time occupancy and usage data, allowing for automated scheduling of cleaning services based on demand rather than a schedule, driving a significant and immediate return on investment for the client.

Barrie Whipp, Chairman, commented: "Cadent is a very prestigious contract win for the Company and we are delighted with the integration with SAP, which opens up further possibilities with this global software supplier. Our Internet of Things offering is quite exciting in the way that it automatically schedules jobs and tasks for mpro5 users to complete. We are very pleased that Incentive has taken its first steps with the platform and we have other pilots in train for IoT which give us optimism for its wider adoption."

 

For further information:

 

Crimson Tide plc

Barrie Whipp / Luke Jeffrey   01892 542 444

 

finnCap (Nominated Adviser and Broker)

Corporate Finance: Julian Blunt / James Thompson  +44 20 7220 0500

Corporate Broking: Andrew Burdis +44 20 7220 0500

 

Alma PR (Financial PR)

Josh Royston +44 7780 901979

 

For further information on Crimson Tide plc, see the website at: www.crimsontide.co.uk/

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAEAXFKFAXEFFA

Close

×

RNS Number : 3454F

Deepverge PLC

16 November 2020

 

16 November 2020

 

DeepVerge PLC

 

("DeepVerge" or "the Company")

 

Update on detection of COVID-19 products

 

First deployments of Microtox PD in Ireland

 

License of patented breathalyser for Microtox BT COVID-19 breath test and initiation of Phase 3 field trials

 

 

DeepVerge has commenced deployment of near-source wastewater contamination test equipment ("Microtox PD") into water treatment plants in Ireland, with first shipments to China and the US expected by year-end.

 

Microtox PD units, retrofitted with AI based optofluidic pathogen identification scanners, are also being shipped to the University of Aberdeen CAT3 laboratory, adding to the ongoing trials with the live SARS-CoV-2, supplied by Public Health England.

 

In addition, DeepVerge has agreed to license a patented breathalyser from PulMoBioMed Limited ("PBM"), a spin-out technology company of Northumbria University, to capture SARS-CoV-2 particles in breath condensate for the DeepVerge optofluidic breath test ("Microtox BT").

 

Phase 3 field trials are expected to begin shortly at multiple sites in Northern England.  In collaboration with EcoWaterOS consortia partners, aggregated anonymised data will provide datasets for AI model simulations from human volunteers who will undergo COVID-19 testing with a combination of Microtox BT, a lateral flow antigen test and a rt-PCR test.  Sufficient datasets are anticipated to be complete early in 2021.

 

Gerard Brandon, CEO of DeepVerge, Commented:

"Phase 3 field trial testing is the last step to establish permanent anonymised mass surveillance of dangerous pathogens in wastewater, in real-time.  The field trials will combine the deployment of Microtox PD wastewater units and daily testing of individual volunteers with a Microtox BT breathalyser test, a lateral flow test and a PCR test.  The data from these tests are expected to simultaneously identify the source of COVID-19 cases, identify COVID-19 clusters, and indicate the size of each cluster in real-time. As the data grows, AI will offer the potential to predict the trajectory of growth of future clusters of Sars-CoV-2 or any future dangerous pathogen.  As we progress towards commercialisation, PulMoBioMed's patented technology will enable a quick roll-out of our Microtox BT breath test once field trials have completed.  We look forward to reporting the results in due course."

 

Dr Sterghios Moschos, MD of PulMoBioMed, added:

"We are delighted to be working with the team at DeepVerge and adding our PBM-Hale device for collecting exhaled breath condensate to the Microtox BT Project, and look forward to combining our respective technologies to deliver a real-time solution for the mass surveillance of COVID-19."

 

 

 

For further information please contact:

DeepVerge plc	Gerard Brandon, CEO	+44 (0) 7340 055 648
SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	+44 (0) 113 370 8974
Turner Pope Investments (TPI) Limited (Broker)	Andy Thacker/Zoe Alexander	+44 (0) 20 3657 0050

 

About DeepVerge plc (www.deepverge.com)

DeepVerge is a scientific research and AI-as-a-Service company focused on production and analysis of bacteria, virus and toxins utilising artificial intelligent data analytics in regulatory technology, from scientifically proving the impact of skincare product claims on skin microbiome for top 10 global cosmetic company clients to remotely detecting water contamination in real-time.

 

In November 2020, DeepVerge acquired Modern Water who developed and commercialised a cutting-edge technology, focused on monitoring of contaminated water and decontamination of wastewater, making recycling of water more efficient. Six countries across the world have legislated that Modern Water monitoring test systems are written into their environmental protection legislation.  The Company is in final trials for its real-time contamination product, Microtox PD, for the identification of COVID-19 hotspots and other pathogens.

 

About EcoWaterOS (www.ecowaterOS.com)

Developed by the Rinocloud division of DeepVerge, this is a consortium of partners operating a live dynamic water management system that delivers safe clear water from rivers to wastewater treatment plants using Artificial Intelligence to provide instant alerts from remote sensors direct to stakeholders. It continuously evolves, learns and improves by bringing together multiple existing and smart technologies to create efficient water and deliver environmental protection. Over-the-air monitoring keeps stakeholders constantly up to date with web and mobile alert applications adapted for each group.

 

About PulMoBioMed Limited

PulMoBioMed is spin-out technology company from Northumbria University who have created a non-invasive device designed to collect exhaled breath condensate free from saliva.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCUSURRRBUAAAA

Close

×

RNS Number : 0210F

NetScientific PLC

11 November 2020

 

NetScientific plc

("NetScientific" or the "Company")

 PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine

 PDS0203 prioritized for clinical development by PDS Biotech and Farmacore after successful meeting with Brazilian Drug Regulatory Agency

London, UK – 11 November 2020 – NetScientific plc (AIM: NSCI), the life sciences, technology investment and commercialisation company, announces that its portfolio company PDS Biotechnology Corporation ("PDS") (Nasdaq: PDSB) announced progress on its co-development program with Farmacore Biotechnology for a Versamune®-based vaccine aimed at preventing COVID-19 infection.

Based on promising and robust preclinical data with PDS0203, and in the interest of rapid development, PDS Biotech and Farmacore have jointly prioritized advancement of PDS0203 to human clinical trials. PDS Biotech had previously announced the parallel development of two Versamune®-based COVID-19 vaccines PDS0203 and PDS0204 each containing different SARS-CoV-2 proteins. The decision to jointly develop PDS0203 was made with the support of the Agência Nacional de Vigilância Sanitária (ANVISA) following a successful pre-investigational new drug meeting on November 06, 2020. ANVISA and Farmacore reviewed the PDS0203 data and agreed on the path forward for official submission of a final data package and the phase 1/2 human clinical trial protocol. Farmacore is in discussions with specific agencies of the government to extend the preclinical funding to cover the upcoming human clinical trial anticipated to begin during the first half of 2021.

 

"PDS0203 may present strong potential to provide the breadth and level of immune responses necessary for a safe and effective vaccine with long-term protection against COVID-19," said Dr. Greg Conn, Chief Scientific Officer of PDS Biotechnology.

 

"PDS Biotech and Farmacore are now one step closer to advancing our Versamune®-based COVID-19 vaccine into the clinic," said Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech. "The preclinical results of PDS0203 demonstrate its potential to induce a robust and broad immune response. We look forward to evaluating our next-generation vaccine in planned human clinical trials in partnership with Farmacore and to advance our understanding of the potential of novel Versamune®-based vaccines like PDS0203 to provide long-term protection against infection with viruses such as SARS-CoV-2."

 

NetScientific holds approximately 5.75% of PDS' undiluted share capital.

The full details of the announcement are set out below and can be found here: https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/56-2020-news/454-iotechandarmacorennouncepdatestooevelopmen20201110

# # #

PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine

 

PDS0203 prioritized for clinical development by PDS Biotech and Farmacore after successful meeting with Brazilian Drug Regulatory Agency

 

FLORHAM PARK, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced progress on its co-development program with Farmacore Biotechnology for a Versamune®-based vaccine aimed at preventing COVID-19 infection.

 

Based on promising and robust preclinical data with PDS0203, and in the interest of rapid development, PDS Biotech and Farmacore have jointly prioritized advancement of PDS0203 to human clinical trials. PDS Biotech had previously announced the parallel development of two Versamune®-based COVID-19 vaccines PDS0203 and PDS0204 each containing different SARS-CoV-2 proteins. The decision to jointly develop PDS0203 was made with the support of the Agência Nacional de Vigilância Sanitária (ANVISA) following a successful pre-investigational new drug meeting on November 06, 2020. ANVISA and Farmacore reviewed the PDS0203 data and agreed on the path forward for official submission of a final data package and the phase 1/2 human clinical trial protocol. Farmacore is in discussions with specific agencies of the government to extend the preclinical funding to cover the upcoming human clinical trial anticipated to begin during the first half of 2021.

 

As previously disclosed, PDS Biotech has generated robust preclinical data demonstrating that PDS0203 elicits a 30-45 fold increase in the induction of highly active and potent virus-specific T-cells within 14 days of treatment compared to the vaccine without Versamune®. Importantly, the study also demonstrated induction of the long-lasting virus-specific memory T-cells necessary for longer term protection. The vaccine has also demonstrated strong and long-lasting induction of neutralizing antibodies. The PDS0203 subunit vaccine is based on recombinant proteins and does not require the use of inactivated viruses, traditional adjuvants, DNA or RNA to induce robust protective immune responses.

 

"PDS0203 may present strong potential to provide the breadth and level of immune responses necessary for a safe and effective vaccine with long-term protection against COVID-19," said Dr. Greg Conn, Chief Scientific Officer of PDS Biotechnology.

 

"PDS Biotech and Farmacore are now one step closer to advancing our Versamune®-based COVID-19 vaccine into the clinic," said Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech. "The preclinical results of PDS0203 demonstrate its potential to induce a robust and broad immune response. We look forward to evaluating our next-generation vaccine in planned human clinical trials in partnership with Farmacore and to advance our understanding of the potential of novel Versamune®-based vaccines like PDS0203 to provide long-term protection against infection with viruses such as SARS-CoV-2."

 

"In this global pandemic, it is incumbent upon the scientific community to be flexible and to ensure we are prioritizing the vaccine with the most clinical potential and that we can progress most quickly," said Helena Faccioli, CEO of Farmacore. "We are excited to continue advancing the partnership with PDS Biotech, and we are thrilled to have the support of ANVISA to provide the opportunity to develop a treatment in Brazil in the fight against this pandemic."

 

The companies plan to utilize multiple research and development sites in the United States and Brazil to progress preclinical and clinical development PDS0203.  Farmacore will lead the regulatory and clinical trial efforts in Brazil while PDS Biotech will continue to contribute scientific expertise and operational support.

 

About PDS Biotechnology

 

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

 

About Farmacore

 

Farmacore is a biotechnology company, founded in 2005 as a startup, focusing on R&D of innovative immunobiological products for use in the human and veterinary health sectors. It is a technology-based company that conducts research and development of biotechnological products and processes for the human and veterinary sectors. It develops innovative biotechnological and immunobiological products and adds value to them in all stages of development, from project design to biomolecule production www.farmacore.com.br.

 

About PDS0203

 

PDS0203 is an investigational vaccine designed for the prevention of COVID-19 being jointly developed by PDS Biotech and Farmacore. PDS0203 combines the utility of PDS Biotech's Versamune® platform with a recombinant native Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) protein recognizable by our immune system (antigen). The Versamune® platform, due to its unique ability to induce both antibody and T-cell responses is being utilized to develop a next generation vaccine that may more effectively prevent COVID-19 .

 

# # #

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Following the publication of this announcement, this inside information is now considered to be in the public domain.

For more information, please contact:

NetScientific 

Ilian Iliev, CEO  Tel: +44 (0)20 3514 1800

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel  Tel: +44 (0)20 7220 1666

 

About NetScientific

NetScientific is a life sciences, technology investment and commercialisation Group, leveraging trans-Atlantic relationships and global opportunities to deliver shareholder value.

For more information, please visit the website at    www.NetScientific.net

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

RESFLFISLTLLLII

Close